|
retinol = vitamin A alcohol the primary dietary source, transport, and storage form
retinal = vitamin A aldehyde
retinoic acid = vitamin A acid = the biologically active form
| • | retinol in the human skin cells must be oxidated to retinoic acid |
| • | metabolism of retinoids occurs mainly in the liver |
| • | beta carotene is converted (in the intestine) to 2 molecules of retinal |
nuclear receptors for retinoids:
| • | belong to a superfamily of receptors that act as DNA transcription factors and include steroid, vitamin D, and thyroid hormone receptors |
| • | retinoid action = “physiologic instead of cytotoxic” i.e. induce differentiation to dysplastic epithelium |
retinoids treat disorders of cornification:
| • | the ichthyoses (hyperproliferative vs. retention hyperkeratosis) |
| • | psoriasis (hyperproliferative epidermis) |
| • | acne (excessive desquamation of follicular epithelium in sebaceous follicles) |
SIDE EFFECTS:
acute toxicity:
| • | pseudotumor cerebri (rare) |
| • | persistent headaches with visual changes, nausea, and vomiting |
| • | d/c and examine for papilledema |
lab abnormalities:
| • | increase triglycerides – dose dependent and reversible |
| • | d/c if levels reach 800mg/dL or higher |
| • | occur in 15% of patients, but usually return to normal within 2 to 4 weeks |
| • | acute hepatotoxic reactions may occur with fever and eosinophilia, possibly indicating hypersensitivity |
chronic toxicity (after long term use; > 2 years)
| • | may result in demineralization of bones, premature closure of epiphysis resulting in shorter stature, and calcification of tendons and ligaments |
SPECIFIC RETINOIDS:
Panretin (alitretinoin) - topical treatment for Kaposi's Sarcoma
Targretin (baxarotene) - oral treatment for Mycoses Fungoides
Guy Webster:
| • | for patient with truncal acne, will start Accutane with PO prednisone (20-40mg/day X first month) to avoid flare with keloids |
| • | rarely re-treats after less than 4 months |
| • | unknown how many times one can retreat (he has treated as often as 6 times) |
| • | 2-4 weeks repeat triglycerides, monitor until they plateau |
| • | 4-6 weeks repeat liver profile (again at end of treatment, or after 4 months) |
| • | contact lenses (extra lubricant, try not to wear overnight) |
|
adverse effects:
| • | acute – increased triglycerides, LFT’s, dryness, hair loss, pseudotumor cerebri |
| • | chronic (>2 years) – demineralization of bones, premature closure of the epiphyses (short stature), calcification of tendons and ligaments |
total dose goal = 120 to 150 mg/kg (typically takes 6 months to achieve this total dose)
|
acitretin:
| • | = the free acid metabolite of etretinate |
| • | decreased potential for post treatment teratogenicity |
|